by Suzanne Burdick, Ph.D. Merck is paying $9.2 billion to acquire a drug company primarily for an experimental antiviral flu-prevention drug, marketed specifically as “not a vaccine.” TrialSite News reported…
November 22, 2025
by Suzanne Burdick, Ph.D. Merck is paying $9.2 billion to acquire a drug company primarily for an experimental antiviral flu-prevention drug, marketed specifically as “not a vaccine.” TrialSite News reported…